Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE

Mepolizumab reduces risk for repeat surgery for chronic rhinosinusitis with nasal polyps

Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine

IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps - Medical Conferences

PDF] Chronic Rhinosinusitis with Nasal Polyps.

Mepolizumab Improves Loss of Smell in Chronic Rhinosinusitis With Nasal Polyps

Mepolizumab add-on shrinks nasal polyp, relieves symptoms in CRSwNP, Latest news for Doctors, Nurses and Pharmacists

PDF) Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy

Eosinophils & MOA NUCALA (mepolizumab) for CRSwNP

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up - Desrosiers - International Forum of Allergy & Rhinology - Wiley Online Library

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine